Percutaneous Device Closure of PVL: An Alternative to Surgery

leak paravalvularParavalvular Leak (PVL) occurs in 5 to 17% of patients undergoing surgical valve replacement. Percutaneous device closure of PVL represents an alternative to repeat surgery.

 

All centers in UK and Ireland performing percutaneous PVL closure delivered their data to the UK PVL registry. Data were analyzed for factors associated with mortality and major cardiovascular events at follow up.

 

There were 308 percutaneous PVL closure procedures in 259 patients between 2004 and 2015 in 20 centers. Population mean age was 67±13 years and 28% were women.

 

Main indication for percutaneous PVL closure was:

  • Cardiac failure, 80% of cases.
  • Hemolysis, 16% of cases.

 

Implantation was successful in 91% of patients via:

  • Transradial (7%)
  • Transfemoral arterial (52%)
  • Transfemoral venous (33%)
  • Transapical (7%)

 

19% of patients required reintervention.

 

Intervened valves were:

  • Mitral, 44%
  • Aortic, 48%.
  • Both, 2%.
  • Pulmonic, 0.4%.
  • TAVR, 5%.

 

Periprocedural leak was severe in 61% and multiple in 37% of cases, and improved significantly after procedure (p<0.001), disappearing in 33.3%, or becoming mild (41.4%) or moderate residual leak (18.6%).

 

Patient functional class also improved significantly at median 110 day follow up.

 

In hospital death was:

  • Elective cases, 2.9%.
  • Urgent cases, 6.8%.
  • Emergency procedures, 50%.

 

[plain]

At follow up, mortality resulted 16%, vascular surgery 6% and late device embolization 0.4%. The mitral valve was associated with more adverse events compared to the rest of the valves.

[/plain]

 

Factors independently associated with death were:

  • Degree of persistent leak (HR 2.87; p=0.037).
  • Functional class at follow up (HR 2.00; p=0.015).
  • Baseline creatinine (HR 8.19; P=0.001).

 

Conclusion

Percutaneous paravalvular leak closure is effective and improves leak severity and symptom severity. Post procedural residual leak severity is independently associated with adverse events and death. Percutaneous PVL closure must be considered an alternative to repeat surgery.

 

Original Title: Percutaneous Device Closure of Paravalvular Leak. Combined Experience From the United Kingdom and Ireland.

Reference: Patrick A. Calvert et al. Circulation. 2016 Sep 27; 134(13):934-44.

 

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

 

We value your opinion. You are more than welcome to leave your comments, suggestions or questions here below.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...